Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 1,451 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Primary Parkinsonism Clear all

Conditions: Parkinson Disease, Off Episodes
Interventions: APL-130277, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more

Conditions: Alzheimer's Disease, Stroke, Parkinson's Disease, Traumatic Brain Injury
Interventions: AVP-923; Drug
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 39
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 31 more

Conditions: Parkinson Disease
Interventions: Placebo, PF-06649751; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 20
States / cities: Phoenix, Arizona • Boca Raton, Florida • Miami, Florida + 11 more

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: StemGenex; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy Adult
Interventions: [¹⁸F]MODAG-009 PET Imaging; Drug
Lead sponsor: MODAG GmbH; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years and older
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson Disease, Huntington Disease
Interventions: No Intervention - Observational Study; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Parkinson Disease
Interventions: DaTscan; Drug
Lead sponsor: Ken Marek, MD; Other
Eligibility: 30 Years and older
Enrollment: 952 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 21
States / cities: Birmingham, Alabama • Sun City, Arizona • La Jolla, California + 17 more

Conditions: Parkinson's Disease
Interventions: Rasagiline, Placebo; Drug
Lead sponsor: Brown University; Other
Eligibility: 40 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Parkinson's Disease, Constipation
Interventions: ENT-01, Placebo; Drug · Other
Lead sponsor: Enterin Inc.; Industry
Eligibility: 30 Years to 86 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 15
States / cities: Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 12 more

Conditions: Parkinson's Disease
Interventions: Respiratory muscle strength training; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 45 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Parkinson's Disease, Exercise Therapy, Cognition
Interventions: PDAE, WAE; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 89 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Executive Dysfunction, Parkinson Disease, Quality of Life
Interventions: High-speed yoga multi-directional yoga; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 50 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Parkinson Disease, Gait Disorders, Neurologic, Visuospatial/Perceptual Abilities
Interventions: Left STN-DBS on, right STN-DBS off first, Right STN-DBS on, left STN-DBS off first; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Predicted Tauopathies, Including, Progressive Supranuclear Palsy, Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17, Corticobasal Degeneration Syndrome, Progressive Nonfluent Aphasia
Interventions: davunetide (AL-108, NAP), Placebo nasal spray; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Exercise, Parkinson's Disease
Interventions: Aerobic vs. Agility Training; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Parkinson Disease
Interventions: Levodopa, Clinical DBS Setting, Sham DBS, DBS Setting Maximizing Prefrontal Activation, DBS Setting Minimizing Prefrontal Activation; Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Parkinson Disease
Interventions: Not listed
Lead sponsor: University of Delaware; Other
Eligibility: 21 Years to 100 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease (PD)
Interventions: The MIND diet; Behavioral
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 30 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Elizabethton, Tennessee • Knoxville, Tennessee

Conditions: Parkinson's Disease
Interventions: TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt); Drug
Lead sponsor: Novartis; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 301 participants
Timeline: 2002 – 2003
U.S. locations: 11
States / cities: Phoenix, Arizona • Berkley, California • Fountain Valley, California + 8 more

Conditions: Parkinson Disease
Interventions: Barre exercise; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Parkinson Disease
Interventions: BHV-8000 10mg, BHV-8000 20 mg, Placebo; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 25
States / cities: Birmingham, Alabama • Sun City, Arizona • Irvine, California + 22 more

Conditions: Parkinson's Disease
Interventions: APL-130277; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 4
States / cities: Sun City, Arizona • Englewood, Colorado • Boca Raton, Florida + 1 more

Conditions: Essential Tremor, Parkinson's Disease, Movement Disorders, Neuropathic Pain
Interventions: Not listed
Lead sponsor: InSightec; Industry
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 5
States / cities: Stanford, California • Baltimore, Maryland • Philadelphia, Pennsylvania + 2 more

Search by objective public record fields.

Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease

Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

Outcomes Data of Adipose Stem Cells to Treat Parkinson's Disease

Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy Volunteers

Ancillary Longitudinal CSF Collection Study in the Harvard Biomarker Study - HBS2

Measuring Cortisol Levels in Persons With Parkinson's (PD)

Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

The Effect of Rasagiline on Cognition in Parkinson's Disease

Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation

Masked Faces in Parkinson Disease: Mechanism and Treatment

Partnered Dance Aerobic Exercise as a Neuroprotective, Motor and Cognitive Intervention in Parkinson's Disease

High-Speed Yoga and Executive Function

Correlation of STN-DBS Induced Visuospatial Changes and Freezing of Gait

Davunetide (AL-108) in Predicted Tauopathies - Pilot Study

The Effects of Treadmill Versus Agility Training in Parkinson's Disease

Cortical Electrophysiology of Response Inhibition in Parkinson's Disease

University of Delaware Parkinson's Disease Registry

The Meals Study for Amyotrophic Lateral Sclerosis and Parkinson's Disease

A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy

Barre Exercise in Parkinson's

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

A Study to Examine APL-130277 in Patients With Parkinson's Disease

Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders: